ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$82.9

Market cap

$1.89B

P/E Ratio

20.17

Dividend/share

N/A

EPS

$4.11

Enterprise value

$2.19B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 91

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
The gross profit has grown by 40% year-on-year and by 3.7% since the previous quarter
Ani Pharmaceuticals's revenue has increased by 37% YoY and by 4.6% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com/
Peers: JAZZ TEVA CLDX PFE

Key stats

What are the main financial stats of ANIP

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
2.88%
1 week
-0.12%
1 month
0.22%
1 year
25.55%
YTD
5.02%
QTD
7.8%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$923.71M
Gross profit
$561.85M
Operating income
$106.42M
Net income
$92.15M
Gross margin
60.8%
Net margin
10%
The gross profit has grown by 40% year-on-year and by 3.7% since the previous quarter
Ani Pharmaceuticals's revenue has increased by 37% YoY and by 4.6% from the previous quarter
The company's operating income rose by 30% QoQ
ANIP's operating margin is up by 24% since the previous quarter

Price vs fundamentals

How does ANIP's price correlate with its fundamentals

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
ANIP P/E details
P/E
20.17
P/B
3.31
P/S
1.93
EV/EBIT
16.28
EV/EBITDA
9.7
EV/Sales
2.37
The company's EPS rose by 17% QoQ
The company's equity rose by 34% YoY and by 4% QoQ
The P/B is 23% above the 5-year quarterly average of 2.6 but 6% below the last 4 quarters average of 3.4
Ani Pharmaceuticals's revenue has increased by 37% YoY and by 4.6% from the previous quarter
The price to sales (P/S) is 10% lower than the 5-year quarterly average of 2.1 and 6% lower than the last 4 quarters average of 2.0

Efficiency

How efficient is Ani Pharmaceuticals business performance
Ani Pharmaceuticals's ROIC has increased by 16% from the previous quarter
The ROA has grown by 16% from the previous quarter
The company's return on sales rose by 11% QoQ
The return on equity has grown by 10% since the previous quarter

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 65% more than its total liabilities
ANIP's quick ratio is up by 31% year-on-year and by 17% since the previous quarter
The company's current ratio rose by 17% YoY and by 15% QoQ
The debt is 9% higher than the equity
The company's equity rose by 34% YoY and by 4% QoQ
The debt to equity has decreased by 27% YoY and by 4.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.